Literature DB >> 17470643

Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.

Jon E Hawkinson1, Balazs G Szoke, Albert W Garofalo, Dennis S Hom, Hongbing Zhang, Mark Dreyer, Juri Y Fukuda, Linda Chen, Bhushan Samant, Stellanie Simmonds, Karla P Zeitz, Angie Wadsworth, Anna Liao, Raymond A Chavez, Wes Zmolek, Lany Ruslim, Michael P Bova, Ryan Holcomb, Eduardo R Butelman, Mei-Chuan Ko, Annika B Malmberg.   

Abstract

The bradykinin B(1) receptor plays a critical role in chronic pain and inflammation, although efforts to demonstrate efficacy of receptor antagonists have been hampered by species-dependent potency differences, metabolic instability, and low oral exposure of current agents. The pharmacology, pharmacokinetics, and analgesic efficacy of the novel benzamide B(1) receptor antagonist 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diazaspiro[5.5]undecanecarbonyl)phenyl]-2,3-dihydro-isoindol-1-one (ELN441958) is described. ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM). ELN441958 potently antagonized DAKD (but not bradykinin)-induced calcium mobilization in IMR-90 cells, indicating that it is highly selective for B(1) over B(2) receptors. Antagonism of agonist-induced calcium responses at B(1) receptors from different species indicated that ELN441958 is selective for primate over rodent B(1) receptors with a rank order potency (K(B), nanomolar) of human (0.12 +/- 0.02) approximately rhesus monkey (0.24 +/- 0.01) > rat (1.5 +/- 0.4) > mouse (14 +/- 4). ELN441958 had good permeability and metabolic stability in vitro consistent with high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. Because ELN441958 is up to 120-fold more potent at primate than at rodent B(1) receptors, it was evaluated in a primate pain model. ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c. Naltrexone had no effect on the antihyperalgesia produced by ELN441958, indicating a lack of involvement of opioid receptors. ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470643     DOI: 10.1124/jpet.107.120352

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Pd-catalyzed arylation of linear and angular spirodiamine salts under aerobic conditions.

Authors:  Sean W Reilly; Nikaela W Bryan; Robert H Mach
Journal:  Tetrahedron Lett       Date:  2016-12-23       Impact factor: 2.415

2.  Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain.

Authors:  Devki D Sukhtankar; Heeseung Lee; Kenner C Rice; Mei-Chuan Ko
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

Review 3.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

Review 4.  Translational value of non-human primates in opioid research.

Authors:  Huiping Ding; Mei-Chuan Ko
Journal:  Exp Neurol       Date:  2021-01-14       Impact factor: 5.330

5.  The bradykinin system in stress and anxiety in humans and mice.

Authors:  Ari Rouhiainen; Natalia Kulesskaya; Marie Mennesson; Zuzanna Misiewicz; Tessa Sipilä; Ewa Sokolowska; Kalevi Trontti; Lea Urpa; William McEntegart; Suvi Saarnio; Petri Hyytiä; Iiris Hovatta
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

6.  Shocking effects of endothelial bradykinin B1 receptors.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2008-05-29       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.